Science News
from research organizations

Protein BVES identified as a suppressor of colorectal cancer progression

Date:
September 12, 2011
Source:
Journal of Clinical Investigation
Summary:
Once a cancer gains the ability to invade local tissues and spread to a distant site it becomes much harder to treat. Researchers have now identified the protein BVES as a suppressor of colorectal cancer progression to this dangerous state, leading them to suggest that BVES could be a therapeutic or preventative target in colorectal cancer.
Share:
       
FULL STORY

Once a cancer gains the ability to invade local tissues and spread to a distant site it becomes much harder to treat. A team of researchers, led by Min Chang and Christopher Williams, at Vanderbilt University School of Medicine, Nashville, has now identified the protein BVES as a suppressor of colorectal cancer progression to this dangerous state, leading them to suggest that BVES could be a therapeutic or preventative target in colorectal cancer.

Cancers originating from cells covering any of the external and internal surfaces of the body (epithelial cells) are known as epithelial cancers. If such cancers (e.g., colorectal cancer) are to become invasive and spread to distant sites in the body, some of the epithelial cancer cells must acquire the characteristics of a different cell type, a mesenchymal cell. Protein complexes that link epithelial cells together (junctional complexes) are regulators of epithelial-mesenchymal transition (EMT).

Chang, Williams, and colleagues found that the junctional protein BVES regulates EMT in human colon cancer cells. Importantly, the team found that BVES expression was reduced in all stages of human colorectal carcinoma and that restoring BVES expression to normal decreased the in vitro and in vivo cancer cell characteristics of human colon cancer cells. These data provide the rational for the suggestion that targeting BVES could be of benefit to individuals with colorectal cancer.

The research is published in the Journal of Clinical Investigation.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Christopher S. Williams, Baolin Zhang, J. Joshua Smith, Ashwath Jayagopal, Caitlyn W. Barrett, Christopher Pino, Patricia Russ, Sai H. Presley, DunFa Peng, Daniel O. Rosenblatt, Frederick R. Haselton, Jin-Long Yang, M. Kay Washington, Xi Chen, Steven Eschrich, Timothy J. Yeatman, Wael El-Rifai, R. Daniel Beauchamp, Min S. Chang. BVES regulates EMT in human corneal and colon cancer cells and is silenced via promoter methylation in human colorectal carcinoma. Journal of Clinical Investigation, 2011; DOI: 10.1172/JCI44228

Cite This Page:

Journal of Clinical Investigation. "Protein BVES identified as a suppressor of colorectal cancer progression." ScienceDaily. ScienceDaily, 12 September 2011. <www.sciencedaily.com/releases/2011/09/110912143252.htm>.
Journal of Clinical Investigation. (2011, September 12). Protein BVES identified as a suppressor of colorectal cancer progression. ScienceDaily. Retrieved May 25, 2015 from www.sciencedaily.com/releases/2011/09/110912143252.htm
Journal of Clinical Investigation. "Protein BVES identified as a suppressor of colorectal cancer progression." ScienceDaily. www.sciencedaily.com/releases/2011/09/110912143252.htm (accessed May 25, 2015).

Share This Page: